KYTRIL
LOE ApproachingNDAORALSOLUTION
Approved
Jun 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 30m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYTRIL (granisetron) is an oral solution small-molecule antiemetic approved in 2001 for chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea/vomiting (PONV). It is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone. The product is a mature, well-established standard-of-care therapy in its indication.
LOE Approaching
Product faces moderate competitive pressure (30/100) with approaching loss of exclusivity, signaling a contracting team and shift toward generic/lifecycle management roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
Started Apr 2007
171 enrolled
Post-Operative Nausea and Vomiting
Career Relevance
KYTRIL represents a mature, cash-generative asset in decline, offering limited career growth but strong operational discipline in a LOE scenario. Roles focus on defending market share, managing generics, and optimizing reimbursement rather than innovation.
Brand Manager
Worked on KYTRIL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.